Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063242 · ClinicalTrials.gov registry record · Phase 2
Sargramostim for Myeloid Dendritic Cell Deficiency
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03063242 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 4 participants.
The verdict
NCT03063242, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with kidney transplants.
Interventions
- BIOLOGICAL Blood samples
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2018-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063242
The ClinicalTrials.gov registry entry for NCT03063242 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood samples is the first listed.
NCT03063242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03063242 about?
NCT03063242 is a clinical study titled "Sargramostim for Myeloid Dendritic Cell Deficiency". The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with kidney transplants.
What is the current status of trial NCT03063242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-02-23. Estimated completion is 2018-09-17.
What interventions are being tested in trial NCT03063242?
The interventions under investigation include: Blood samples (BIOLOGICAL), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT03063242?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.